Drugs & Targets FDA approves Gomekli for pediatric patients with neurofiromatosis type 1 February 14, 2025Vol.51 No.06
Black History MonthFreeIn the Archives Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”Preserving an oral history by the former FDA associate commissioner of women’s heath February 07, 2025Vol.51 No.05By Katie Goldberg
Drugs & Targets FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy February 07, 2025Vol.51 No.05
White House Tracking Trump’s early impact on cancer policyResearch and care disrupted, NCI programs face unpredictable future January 31, 2025Vol.51 No.04By Paul Goldberg
Drugs & Targets FDA approves Enhertu as first HER2-directed therapy for breast cancer January 31, 2025Vol.51 No.04
Drugs & Targets FDA approves Grafapex as preparative regiment for allogeneic hematopoietic stem cell transplantation in AML or MDS January 31, 2025Vol.51 No.04
Drugs & Targets FDA grants RP1 BLA priority review for advanced melanoma January 24, 2025Vol.51 No.03
Guest Editorial FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials January 17, 2025Vol.51 No.02By Laura A. Levit, Mark J. Ratain, Julie R. Gralow, Clifford A. Hudis and Elizabeth Garrett-Mayer
Drugs & Targets FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer January 17, 2025Vol.51 No.02
